Camsirubicin (MNPR-201; formerly GPX-150)

Camsirubicin is covered by both composition of matter as well as manufacturing process patents. A novel chemical composition of an intermediate for this synthesis is also patented. In addition, we have a method of use patent covering the combination of camsirubicin with paclitaxel for the treatment of cancer. Our camsirubicin patent portfolio contains seven issued and allowed U.S. patents and one U.S. pending patent application that covers additional analogs of camsirubicin. We have corresponding patents and applications in 29 foreign jurisdictions, including the U.S., EU, Japan, and other Asian countries. We have obtained orphan drug status in the U.S. and EU for soft tissue sarcoma.

MNPR-101 RIT (Radio-immuno-therapeutic)

Patent applications have been filed with the U.S. Patent and Trademark Office covering the use of uPAR-targeted RITs for the treatment of severe COVID-19 and a composition of matter patent covering MNPR-101-PCTA-Ac225.

MNPR-101 (formerly huATN-658)

Monopar's patent portfolio for MNPR-101, as well as its epitope, consists of two issued U.S. composition of matter and their method of use patents, and allowed patent applications and corresponding (granted and pending) patents and patent applications in 22 foreign jurisdictions, including the European Union, Japan, and other Asian countries.

MNPR-202 (Camsirubicin analog)

MNPR-202 is covered by U.S. patent (US10,450,340) which protects the composition of matter for MNPR-202 and related analogs. The patent is expected to expire in 2038, not including any patent term extensions.